Version history

{
  "session_id": "sess_SDA-2026-04-10-gap-debate-20260410-075000-7396040a_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"TDP-43 condensation thermodynamics as a therapeutic target and biomarker for nuclear-cytoplasmic compartmentalization\",\n      \"description\": \"FRAP-based measurement of TDP-43 liquid-liquid phase separation state provides a continuous biomarker of nuclear-cytoplasmic compartmentalization. Endogenous TDP-43-eGFP knock-in in iPSC neurons enables longitudinal monitoring; orthogonal validation via mAb414 nuclear pore integrity anchors imaging to ultrastructure. Primary constraint is imaging endpoint gap—two-photon FRAP is not deployable in standard trials; PET ligand development is the critical path to clinical utility.\",\n      \"target_gene\": \"TARDBP (TDP-43 protein); IPO4/IP09 (nuclear import receptors as secondary targets)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.72,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.68,\n        \"therapeutic_potential\": 0.72,\n        \"mechanistic_plausibility\": 0.78,\n        \"druggability\": 0.65,\n        \"safety_profile\": 0.82,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.72\n      },\n      \"composite_score\": 0.71,\n      \"evidence_for\": [\n        {\"claim\": \"TDP-43 pathology present in >95% of ALS cases\", \"pmid\": \"19042910\"},\n        {\"claim\": \"Nuclear import defects cause cytoplasmic TDP-43 accumulation\", \"pmid\": \"30540933\"},\n        {\"claim\": \"Phase separation of TDP-43 directly observed by super-resolution microscopy\", \"pmid\": \"31439799\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"FRAP measures protein mobility influenced by viscosity and crowding, not exclusively liquid-to-solid transition; cannot distinguish phase separation defects from nuclear import defects without orthogonal anchor\", \"pmid\": null},\n        {\"claim\": \"TDP-43 aggregates may form via mechanisms distinct from liquid-to-solid phase transition, making FRAP kinetics an indirect read-out\", \"pmid\": null}\n      ]\n    },\n    {\n      \"title\": \"Retromer-dependent retrograde endosomal signaling compartmentalization as biomarker and intervention point\",\n      \"description\": \"VPS26/VPS29/VPS35 retromer complex maintains axonal endosomal signaling microdomains controlling TrkB/p75NTR trafficking. Impaired retromer causes somatodendritic receptor mislocalization disrupting synaptic plasticity. TrkB-mScarlet time-lapse imaging in microfluidic chambers provides compartmentalization index (somatic/axonal fluorescence ratio). CCN1 bicyclic peptide is proof-of-mechanism agonist but requires IND-enabling studies. VPS35 P294S variant increases AD risk; VPS35 mutations linked to late-onset PD.\",\n      \"target_gene\": \"VPS35, VPS26, VPS29 (retromer complex); TrkB/NTRK2 (cargo receptors)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.62,\n        \"feasibility\": 0.55,\n        \"therapeutic_potential\": 0.65,\n        \"mechanistic_plausibility\": 0.68,\n        \"druggability\": 0.58,\n        \"safety_profile\": 0.75,\n        \"competitive_landscape\": 0.68,\n        \"data_availability\": 0.55,\n        \"reproducibility\": 0.60\n      },\n      \"composite_score\": 0.62,\n      \"evidence_for\": [\n        {\"claim\": \"VPS35 P294S variant increases Alzheimer's disease risk\", \"pmid\": \"23314016\"},\n        {\"claim\": \"VPS35 mutations linked to late-onset Parkinson's disease\", \"pmid\": \"22036963\"},\n        {\"claim\": \"Retrograde axonal transport defects precede motor symptoms in PD models\", \"pmid\": \"24722928\"},\n        {\"claim\": \"Retromer agonism by bicyclic peptide CCN1 enhances neurotrophin signaling\", \"pmid\": \"29249286\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"No published lead compounds for retromer enhancement; CCN1 has not entered IND-enabling studies\", \"pmid\": null},\n        {\"claim\": \"Retromer enhancement is a maintenance strategy; may not reverse established trafficking defects; therapeutic window likely limited to prodromal disease stages\", \"pmid\": null}\n      ]\n    },\n    {\n      \"title\": \"A genetically encoded reporter for axonal mitochondrial protein import fidelity as a biomarker of compartmentalization\",\n      \"description\": \"MTS-dGFP fusion construct requires intact TOM40/TOM20 translocase for mitochondrial import, serving as direct read-out of compartmentalized proteostasis capacity. CHOP promoter-driven alternative fluorophore provides stress-responsive signal. Cryo-EM of import pores in same cells anchors ratiometric imaging to ultrastructure. Primary flaw: reporter fails entirely when import machinery is impaired (ceiling effect), generating false-negatives indistinguishable from severe pathology.\",\n      \"target_gene\": \"TOM20, TOM40 (translocase complex); CHOP/DDIT3 (stress response promoter)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.55,\n        \"novelty\": 0.52,\n        \"feasibility\": 0.58,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.48,\n        \"druggability\": 0.52,\n        \"safety_profile\": 0.70,\n        \"competitive_landscape\": 0.60,\n        \"data_availability\": 0.58,\n        \"reproducibility\": 0.52\n      },\n      \"composite_score\": 0.54,\n      \"evidence_for\": [\n        {\"claim\": \"Mitochondrial import defects documented in ALS models\", \"pmid\": \"30209046\"},\n        {\"claim\": \"Axonal mitochondrial dysfunction precedes neurodegeneration in AD models\", \"pmid\": \"27545678\"},\n        {\"claim\": \"TOMM20 level alterations serve as biomarker in patient-derived neurons\", \"pmid\": \"31196453\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"TOM40 dysfunction is downstream of TDP-43 aggregation; global mitochondrial defects, not compartment-specific\", \"pmid\": \"30209046\"},\n        {\"claim\": \"TOMM20 immunoreactivity measures protein abundance, not import fidelity; cannot distinguish functional from non-functional import capacity\", \"pmid\": \"31196453\"},\n        {\"claim\": \"Mitochondrial defects are consequence of compartmentalization breakdown, not direct measure of it\", \"pmid\": null}\n      ]\n    },\n    {\n      \"title\": \"Co-translational mRNA localization as a sensor for RNA granule trafficking defects in neurodegeneration\",\n      \"description\": \"Local protein synthesis at synaptic compartments requires intact mRNA granule transport via ZBP1 and TDP-43 in granules. Disruption measured by imaging β-actin and CaMKIIα mRNA in proximal neurites; FUNCAT samples nascent synaptic proteome. Domain expert rates as research-grade readout requiring substantial endpoint translation work. Primary weakness: research tool not yet de-risked for clinical biomarker deployment.\",\n      \"target_gene\": \"IGF2BP1 (ZBP1), TARDBP (TDP-43 in RNA granules); β-actin ACTB, CaMKIIα CAMK2A (local translation targets)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.50,\n        \"novelty\": 0.58,\n        \"feasibility\": 0.45,\n        \"therapeutic_potential\": 0.50,\n        \"mechanistic_plausibility\": 0.55,\n        \"druggability\": 0.48,\n        \"safety_profile\": 0.72,\n        \"competitive_landscape\": 0.62,\n        \"data_availability\": 0.50,\n        \"reproducibility\": 0.50\n      },\n      \"composite_score\": 0.52,\n      \"evidence_for\": [\n        {\"claim\": \"Local translation at synapses is established neuroscience; ZBP1-mediated β-actin mRNA transport well-documented\", \"pmid\": null}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Domain expert: requires substantial endpoint translation work before clinical biomarker deployment\", \"pmid\": null},\n        {\"claim\": \"FUNCAT is technically specialized and not standardized across labs; reproducibility concerns for clinical validation\", \"pmid\": null}\n      ]\n    },\n    {\n      \"title\": \"Sonic hedgehog pathway compartmentalization as quantitative biomarker for neuronal polarity defects\",\n      \"description\": \"FRET-based cAMP sensors (Epac1-camps) targeted to primary cilium (ARL13B anchor) and synaptic compartment (PSD95 anchor) provide ratiometric read-out of compartmentalized signaling. SMO agonist pharmacological challenge tests reserve capacity. Critical weakness: ciliary signaling evidence base concerns Huntington's disease and neurodevelopmental disorders—not adult-onset ALS/AD. Mechanistic link from developmental ciliary defects to progressive adult neurodegeneration is unsubstantiated.\",\n      \"target_gene\": \"ADCY3 (adenylate cyclase), ARL13B (ciliary targeting), GNAI1/GNAI3 (GPCR signaling)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.45,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.42,\n        \"mechanistic_plausibility\": 0.38,\n        \"druggability\": 0.45,\n        \"safety_profile\": 0.68,\n        \"competitive_landscape\": 0.72,\n        \"data_availability\": 0.42,\n        \"reproducibility\": 0.40\n      },\n      \"composite_score\": 0.46,\n      \"evidence_for\": [\n        {\"claim\": \"Ciliary signaling defects in Huntington's disease\", \"pmid\": \"31138801\"},\n        {\"claim\": \"Ciliopathy phenotypes in iPSC neurons with neurodevelopmental disorders\", \"pmid\": \"29712963\"},\n        {\"claim\": \"Synaptic polarity establishment requires compartmentalized cAMP signaling\", \"pmid\": \"28335004\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Primary cilia primarily studied in dividing cells and specialized neurons; evidence thin for cortical/spinal motor neurons relevant to ALS/AD\", \"pmid\": null},\n        {\"claim\": \"Ciliopathies produce developmental phenotypes; adult-onset neurodegeneration involves distinct mechanisms—mechanistic link unsubstantiated\", \"pmid\": null},\n        {\"claim\": \"SMO agonist measures pathway responsiveness, not structural compartmentalization integrity\", \"pmid\": null},\n        {\"claim\": \"FRET sensor cross-talk and bleedthrough between compartments will produce artifactual ratiometric signals in single-axon imaging\", \"pmid\": null}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"hypothesis_3\", \"source_type\": \"hypothesis\", \"target_id\":",
  "tokens_used": "2480",
  "persona_id": "persona-synthesizer"
}